Sorafenib News and Research

RSS

Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).

Identifying immunotherapy resistance in liver cancer linked to steatotic disease

A research team of Canadian and French scientists, led by INRS professor Maya Saleh, has been investigating immunotherapy resistance in certain patients with hepatocellular carcinoma (HCC) associated with steatotic liver disease.

14 Feb 2024

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

The immune-modulatory effect of lenvatinib investigated in new study

Researchers explore the effect of lenvatinib treatment on patients with advanced thyroid cancer.

9 Aug 2023

Molecular insights into drug-induced GDF15 regulation in cancer cells and cardiomyocytes: implications for precision medicine

A recent study elucidated the molecular mechanisms of drug-induced regulation of growth differentiation factor 15 (GDF15).

1 Aug 2023

Adolescent and young adult kidney cancer survivors at elevated risk for heart problems

New research out of VCU Massey Cancer Center indicates that many adolescent and young adult kidney cancer survivors are at a significantly elevated risk for heart issues.

5 Jul 2023

Nirogacestat shows promising results in patients with desmoid tumors

When Dana Avellino, now 36, first noticed a lump near her groin in the summer of 2018, she thought it was related her recent cesarean section. Her younger daughter was only 2 months old at the time.

9 Mar 2023

Review focuses on the link between the pathogenesis and management of hepatocellular carcinoma

A new review was published in Genes & Cancer on December 13, 2022, entitled, "Pathogenesis to management of hepatocellular carcinoma."

9 Jan 2023

Combination of radiation and systemic therapy can prolong survival for advanced liver cancer patients

Adding radiation therapy to systemic therapy for patients with advanced liver cancer can extend overall survival and delay tumor progression without compromising patients' quality of life, a randomized phase III clinical trial shows.

24 Oct 2022

Treatment resistance for deadly form of kidney cancer linked to low mitochondrial content in the cell

Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell.

27 Jun 2022

Novel targets for treating sorafenib-resistant hepatocellular carcinoma found using CRISPR-Cas9 screening

This study is led by Xiujun Cai (Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine). Professor Xiujun Cai's research team screened the whole genome of hepatocellular carcinoma cells (HepG2) through CRISPR / cas9 system under sorafenib treatment, and screened the dominant gene in sorafenib resistance.

20 Apr 2022

Study shows how SARS-CoV-2 viral proteases can be targeted to stop virus replication

Researchers at the University of Liverpool have shown how SARS-CoV-2 viral proteases attack the host cell, and how this can be targeted to stop virus replication in cell culture using existing drugs.

21 Sep 2021

Study examines effect of sorafenib in patients with advanced hepatocellular carcinoma

Oncotarget published "Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib" which reported that this study investigated the association of the IGF/CTP score with overall survival and progression-free survival of HCC patients treated with sorafenib.

28 Jun 2021

Study shows how m6A regulators influence metabolic heterogeneity of hepatocellular carcinoma

Cancer cells acquire growth advantages over normal cells in myriad ways. Changes in cell programming allow these cells to grow in an uncontrolled fashion, thereby forming the cancer mass.

23 Feb 2021

Pharmacophore model helps find key protease inhibitor responsible for COVID-19

A team of San Diego Supercomputer Center (SDSC) researchers recently created a pharmacophore model and conducted data mining of the database of drugs approved by the U.S. Federal Drug Administration (FDA) to find potential inhibitors of papain-like protease of SARS-CoV2, one of the main viral proteins responsible for COVID-19.

2 Dec 2020

Phase IIB clinical trial initiated for treating hepatitis B-associated liver cancer

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

19 May 2020

New treatment improves survival for people with common liver cancer

For the first time in over a decade, scientists have identified a first-line treatment that significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.

13 May 2020

A new combinatorial therapy for treatment of liver cancer

In the latest issue of Molecular Therapy, Skoltech and MIT researchers have published a new combinatorial therapy for the treatment of liver cancer.

20 Apr 2020

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.

21 Mar 2020

Levels of sBTLA proteins may be a marker of overall survival in patients with HCC

In the 2020 February 25 issue of Scientific Reports, a research group from the Department of Hepatology in Osaka City University Graduate School of Medicine, Japan reported that levels of a circulating soluble immune checkpoint protein can be used as a potential marker to predict overall survival in patients with advanced HCC.

9 Mar 2020

Scientists discover potential drug compounds that target common type of liver cancer

Scientists from the Cancer Science Institute of Singapore at the National University of Singapore, and the Agency for Science, Technology and Research (A*STAR)'s Genome Institute of Singapore have discovered four potential drug compounds that target hepatocellular carcinoma, the most common type of liver cancer.

30 Dec 2019